Regular PaperCyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis
References (11)
- et al.
Cyclosporin treatment of autoimmune chronic active hepatitis
Gastroenterology
(1987) - et al.
Clinical features and prognosis of severe chronic active liver disease after corticosteroid induced remission
Gastroenterology
(1980) - et al.
Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen negative chronic active hepatitis
Gastroenterology
(1987) - et al.
Liver physiology and disease
Gastroenterology
(1972) Autoimmune hepatitis: current approaches
Contemporary Gastroenterol
(1992)
There are more references available in the full text version of this article.
Cited by (101)
Current paradigm and treatment options for autoimmune hepatitis
2023, Comprehensive Guide to Hepatitis AdvancesAutoimmune hepatitis: Challenges and novelties
2022, Medicina ClinicaA reasoned approach to the treatment of autoimmune hepatitis
2021, Digestive and Liver DiseaseUse of immunosuppression in non-transplant hepatology
2021, Best Practice and Research: Clinical GastroenterologyAutoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management
2015, Clinical Gastroenterology and HepatologyCitation Excerpt :CSA appears to be safe and efficacious as an alternative therapy for AIH. In 1 report, CSA therapy (3 mg/kg/d) normalized or nearly normalized ALT within 10 weeks in 5 of 6 adults with type 1 AIH (1 with possible AIH-PSC OS) who had failed treatment with steroids or steroids and AZA.174 Biochemical remissions were sustained for up to 1 year.
Copyright © 1994 Published by Elsevier Ireland Ltd.